PREDICTING THE EFFECTIVENESS OF TREATMENT WITH ROFLUMILAST IN CHRONIC OBSTRUCTIVE PULMONARY DISEASE

There were studied the possibilities of predicting the effectiveness of treatment with roflumilast in the complex therapy of patients with chronic obstructive pulmonary disease (COPD) with low and high risk by assessing the clinical and functional parameters (lung function, severity of respiratory complaints, frequency of exacerbations in the previous year) and serum indicators of systemic inflammation (C-reactive protein, TNF-α, IL-6, IL-8, fibrinogen). One-year study included 60 patients with COPD, among whom there were 22 patients with low risk (group 1) and 38 patients with high risk (group 2), according to the multi-faceted classification of disease. Each group was divided into 2 subgroups depending on the response to treatment: subgroup A included the patients whose therapy was effective and subgroup B consisted of the patients whose therapy was not effective. The criteria for the effectiveness of the treatment were: group 1 - the absence of exacerbations during a year or 1 episode that did not require hospitalization, the initial test CAT (COPD Assessment Test) - 10 points and lower, dyspnea on the mMRC scale no more than 2 points, an increase in FEV₁ by 11% or more; in patients of group 2 the number of exacerbations was 0 or no more than 2 and they did not require hospitalization, dyspnea on the mMRC scale was no more than 2 points, there was no decrease in FEV₁. The effectiveness of treatment was evaluated in points (4 points meant effective treatment, below 4 points - not effective treatment). It was found out that in group 1 in subgroup A after treatment the results of CAT (p<0.001), IL-8 (p<0.001), TNF-α (p<0.001) were significantly lower than in group B (p<0.001). In group 2 after treatment in subgroup A test CAT (p<0.001), CRP (p<0.001) and IL-6 (p<0.01) were significantly lower than in subgroup B. The revealed regularities formed the basis for the creation of mathematical model for predicting the effective application of roflumilast by discriminant analysis for different phenotypes of the disease which allow clinicians to solve the problem of a personalized approach to the selection of patients with COPD with low and high risk.

chronic obstructive pulmonary disease, prognosis, systemic inflammation, exacerbation, roflumilast

1. Белевский А.С., Нуралиева Г.С., Авдеев С.Н., Неклюдова Г.В. Применение нового противовоспалительного препарата рофлумиласт у больного хронической обструктивной болезнью легких // Практическая пульмонология. 2015. №2. С.57-60.

2. Колосов В.П., Павленко В.И. Прогнозирование частоты обострения хронической обструктивной болезни легких, сочетанной с ишемической болезнью сердца // Бюллетень физиологии и патологии дыхания. 2012. Вып.45. С.35-37.

3. Кулик Е.Г., Нарышкина С.В., Павленко В.И. Влияние ингибиторов фосфодиэстеразы-4 на функциональное состояние сосудистого эндотелия у больных хронической обструктивной болезнью легких // Тихоокеанский медицинский журнал. 2015. №4(62). С.53-55.

4. Овчаренко С.И., Галецкайте Я.К. Эволюция глобальной инициативы по хронической обструктивной болезни легких и новый подход к противовоспалительной терапии // Лечащий врач. 2014. №1. С.75-81.

5. Павленко В.И., Кулик Е.Г., Нарышкина С.В. Оценка эффективности применения препарата рофлумиласт в комплексной терапии больных хронической обструктивной болезнью легких с частыми обострениями // Аллергология и иммунология. 2017. Т.18, №4. С.231.

6. Провоторов В.М., Будневский А.В., Шишкина Е.С. Динамика качества жизни у больных с хронической обструктивной болезнью легких в стадии обострения и сопутствующей ишемической болезнью сердца при применении рофлумиласта // Перспективы науки. 2017. №3(90). С.38-42.

7. Прозорова Г.Г., Будневский А.В., Овсянников Е.С., Дробышева Е.С., Шкатова Я.С. Роль системного воспаления у больных хронической обструктивной болезнью легких // Научно-медицинский вестник Центрального Черноземья. 2017. №67. С.152-158.

8. Савелихина И.А., Островский Н.Н. Особенности нарушений функции внешнего дыхания у пациентов с хронической обструктивной болезнью легких III стадии в процессе комплексного лечения с использованием рофлумиласта // Вестник Витебского ГМУ. 2013. Т.12, №3. С.48-54.

9. Кьяв Со А. Обострение как прогностически неблагоприятный фактор хронической обструктивной болезни легких // Пульмонология. 2018. Т.28, №1. С.104-109. https://doi.org/10.18093/0869-0189-2018-28-1-104-109

10. Чучалин А.Г., Авдеев С.Н., Айсанов З.Р., Белевский А.С., Лещенко И.В., Мещерякова Н.Н., Овчаренко С.И., Шмелев Е.И. Российское респираторное общество. Федеральные клинические рекомендации по диагностике и лечению хронической обструктивной болезни легких // Пульмонология. 2014; №3. С.15-54. https://doi.org/10.18093/0869-0189-2014-0-3-15-54

11. Miller M.R., Crapo R., Hankinson J., Brusasco V., Burgos F., Casaburi R., Coates A., Enright P., van der Grinten C.P., Gustafsson P., Jensen R., Johnson D.C., MacIntyre N., McKay R., Navajas D., Pedersen O.F., Pellegrino R., Viegi G., Wanger J.; ATS/ERS Task Force. General considerations for lung function testing. General considerations for lung function testing // Eur. Respir. J. 2005; Vol.26, №1. Р.153-161.

12. Miravitlles M., Huerta A., Valle M., García-Sidro P., Forné C., Crespo C., López-Campos J.L. Clinical variables impacting on the estimation of utilities in chronic obstructive pulmonary disease // Int. J. Chron. Obstruct. Pulmon. Dis. 2015. Vol.10. Р.367-377. doi: 10.2147/COPD.S76397

13. Rabe K.F. Roflumilast for the treatment of chronic obstructive pulmonary disease // Expert Rev. Resp. Med. 2010. Vol.4, №5. P.543-545. doi: 10.1586/ers.10.56

14. Rennard S.I., Calverley P.M., Goehring U.M., Bredenbröker D., Martinez F.J. Reduction of exacerbations by the PDE4 inhibitor roflumilast - the importance of defining different subsets of patients with COPD // Respir. Res. 2011. Vol.12. P.18. doi: 10.1186/1465-9921-12-18

15. Belevskiy A.S., Nuraliyeva G.S., Avdeev S.N., Neklyudova G.V. The use of a new anti-inflammatory drug roflumilast in patients with chronic obstructive pulmonary disease. Prakticheskaya pul’monologiya 2015; 2:57-60 (in Russian).

16. Kolosov V.P., Pavlenko V.I. Рrognostication of the frequency of chronic obstructive pulmonary disease exacerbation combined with the ishemic heart disease. Bûlleten' fiziologii i patologii dyhaniâ 2012; 45:35-37 (in Russian).

17. Kulik E.G., Naryshkina S.V., Pavlenko V.I. The influence of phosphodiesterase-4 inhibitor on the functional condition of vascular endothelium in patients with chronic obstructive pulmonary disease. Pacific Medical Journal 2015; 4:53-55 (in Russian).

18. Ovcharenko S.I., Galetskayte Ya.K. Еvolution of the Global initiative for chronic obstructive lung disease and a new approach to anti-inflammatory therapy. Lechashchiy vrach 2014. №1. S.75-81(in Russian).

19. Pavlenko V.I., Kulik E.G., Naryshkina S.V. Еvaluation of the efficacy roflumilast in the treatment of patients with chronic obstructive pulmonary disease with frequent exacerbations. Allergologiya i immunologiya 2017; 18(4):231 (in Russian).

20. Provotorov V.M., Budnevsky A.V., Shishkina E.S. Dynamics of Quality of Life in Patients with Chronic Obstructive Pulmonary Disease in the Acute Stage and Related Ischemic Heart Disease When Using Roflumilast. Reports Scientific Society 2017; 3:38-42 (in Russian).

21. Prozorova G.G., Budnevskiy A.V., Ovsyannikov E.S., Drobysheva E.S., Shkatova Ya.S. The role of systemic inflammation in patients with chronic obstructive pulmonary disease. Nauchno-meditsinskiy vestnik Tsentral’nogo Chernozem’ya 2017; 67:152-158 (in Russian).

22. Savelikhina I.A., Ostrovskiy N.N. Features of infringements of function of external respiration in patients with chronic obstructive lung disease stage 3 in the process of complex treatment with the use of roflumilast. Vestnik Vitebskogo Gosudarstvennogo Meditsinskogo Universiteta 2013; 12(3):48-54 (in Russian).

23. Kyaw Soe A. Acute exacerbations as a poor prognostic factor of chronic obstructive pulmonary disease. Russian Pulmonology 2018; 28(1):104-109 (in Russian). https://doi.org/10.18093/0869-0189-2018-28-1-104-109

24. Chuchalin A.G., Avdeev S.N., Aysanov Z.R., Belevskiy A.S., Leshchenko I.V., Meshcheryakova N.N., Ovcharenko S.I., Shmelev E.I. Russian Respiratory Society. Federal Guidelines on diagnosis and treatment of chronic obstructive pulmonary disease. Russian Pulmonology 2014; (3):15-54 (in Russian). https://doi.org/10.18093/0869-0189-2014-0-3-15-54

25. Miller M.R., Crapo R., Hankinson J., Brusasco V., Burgos F., Casaburi R., Coates A., Enright P., van der Grinten C.P., Gustafsson P., Jensen R., Johnson D.C., MacIntyre N., McKay R., Navajas D., Pedersen O.F., Pellegrino R., Viegi G., Wanger J.; ATS/ERS Task Force. General considerations for lung function testing. General considerations for lung function testing. Eur. Respir. J. 2005; 26(1):153-161.

26. Miravitlles M., Huerta A., Valle M., García-Sidro P., Forné C., Crespo C., López-Campos J.L. Clinical variables impacting on the estimation of utilities in chronic obstructive pulmonary disease. Int. J. Chron. Obstruct. Pulmon. Dis. 2015; 10:367-377. doi: 10.2147/COPD.S76397

27. Rabe K.F. Roflumilast for the treatment of chronic obstructive pulmonary disease. Expert Rev. Resp. Med. 2010; 4(5):543-545. doi: 10.1586/ers.10.56

28. Rennard S.I., Calverley P.M., Goehring U.M., Bredenbröker D., Martinez F.J. Reduction of exacerbations by the PDE4 inhibitor roflumilast - the importance of defining different subsets of patients with COPD. Respir. Res. 2011; 12:18. doi: 10.1186/1465-9921-12-18